Effect of Second Cycle Pre-induction Chemotherapy in Critically Ill Burkitt’s Lymphoma Children
Cancer Research Journal
Volume 7, Issue 1, March 2019, Pages: 25-32
Received: Feb. 16, 2019;
Accepted: Mar. 25, 2019;
Published: Apr. 18, 2019
Views 194 Downloads 23
Emad Moussa, Department of Clinical Oncology, Menufiya University, Shebeen, Egypt; Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo, Egypt
Asmaa Hamoda, Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo, Egypt; Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
Samah Semary, Department of Pediatric Oncology, Children Cancer Hospital Egypt, Cairo, Egypt; Department of Clinical Oncology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
Marwa Romeih, Department of Radiodiagnosis, Faculty of Medicine, Helwan University, Helwan, Egypt; Department of Radiodiagnosis, Children Cancer Hospital Egypt, Cairo, Egypt
Randa Amin, Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt; Department of Pathology, Children Cancer Hospital Egypt, Cairo, Egypt
Omneya Hassanin, Department of Clinical Research, Children Cancer Hospital Egypt, Cairo, Egypt
Advanced stage Burkiit’s lymphoma (BL) is associated with tumor burden. Toxicities from intensive therapies are significant. The objectives of this study were to analyze the outcome of patients who could not receive induction chemotherapy on time, and were given a 2nd pre-phase (CVP), and to measure the impact of delay on disease outcome. It is a retrospective non randomized study included pediatric patients, suffering from Burkitt’s Lymphoma over 8 years period in CCHE. The result showed that, four hundred and eight patients were diagnosed as Burkitt’s Lymphoma from July 2007 till October 2015, 286 patients (70.1%) received induction on time as per protocol, while 122 patients (29.9%) were not fit to receive their induction chemotherapy on due time. The delay ranged from 6-45 days. While forty five patients (36.88%) out of the delayed patients received 2nd CVP, 16 patients (13.1%) showed relapse/progression. OS among delayed patients who received 2nd CVP versus those who were delayed and were able to receive full induction chemotherapy was (76.1%), (88.7%) respectively. OS in patients who were delayed versus those who were not delayed was (84%), (85.9%) respectively. In conclusion, in critically ill patients delay of chemotherapy in induction phase is important to reduce morbidity and mortality. The delay of chemotherapy has no impact on OS in Burkitt’s lymphoma children. A second pre-phase therapy in our opinion should not be adopted for all critical ill patients who will not tolerate intensive therapy during early phases of treatment, but instead we recommend a recovery from organ toxicity and starting intensive therapy (COPADM) rather than giving 2nd CVP with careful surveillance of disease progression.
Effect of Second Cycle Pre-induction Chemotherapy in Critically Ill Burkitt’s Lymphoma Children, Cancer Research Journal.
Vol. 7, No. 1,
2019, pp. 25-32.
Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL. Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future Pediatr Blood Cancer 200545 (6) 753–769.769.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pieleri SA, Stein H, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. ((IARC WHO Classification of tumours, n.2).
Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis Oncologist 200611 (4) 375–383.383.
Buckle, G, Maranda, L, Skiles, J, et al. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: a historical cohort study. Int J Cancer. 2016; 139: 1231– 1240.
Magrath, IT. Treatment of Burkitt lymphoma in children and adults: lessons from Africa. Curr Hematol Malig Rep. 2006; 1: 230– 240.
LAILA M. SHERIEF, 1, 2 USAMA R. ELSAFY, 1 ELHAMY R. ABDELKHALEK, 1, 2 , et al, Disease patterns of pediatric non-Hodgkin lymphoma: A study from a developing area in Egypt. Mol Clin Oncol. 2015 Jan; 3(1): 139–144.
Catherine Patte, Anne Auperin, Jean Michon, et al, The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia , Blood 2001 97:3370-3379; doi: https://doi.org/10.1182/blood.V97.11.3370
Hesseling, P, Israels, T, Harif, M, Chantada, G, Molyneux, E. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer. 2013; 60: 357– 362.
Cervio, C, Barsotti, D, Ibanez, J, Paganini, H, Sara Felice, M, Chantada, GL. Early mortality in children with advanced mature B‐cell malignancies in a middle‐income country. J Pediatr Hematol Oncol. 2012; 34: e266– 270.
Armando Peña‐Hernandez , Roberta Ortiz , Claudia Garrido , et al, Outcome of pediatric non‐Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA), First published: 24 January 2019, https://doi.org/10.1002/pbc.27621.
Yohannes Belay, Ketsela Yirdaw and Bamlaku Enawgaw 2 Tumor Lysis Syndrome in Patients with Hematological Malignancies, J Oncol. 2017; 2017: 9684909.
Tsurusawa M1, Gosho M1, Mori T2, et al, Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma, Pediatr Blood Cancer. 2015 Feb; 62(2):279-284. doi: 10.1002/pbc.25305. Epub 2014 Oct 30.
Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95 Blood 2005105 (3) 948–958.958.
Faizan, M., Anwar, S. & Khan, S. (2018) Demographics and outome in paediatric non-Hodgkin lymphoma: single centre experience at The Children Hospital Lahore, Pakistan. Journal of the College of Physicians and Surgeons Pakistan, 28, 48–51.
Cairo, M. S., Coiffier, B., Reiter, A. & Younes, A.; TLS Expert Panel. (2010) Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British Journal of Haematology, 149, 578–586.
Gaytan-Morales F, Alejo-Gonzalez F, Reyes-Lopez A, et al: Pediatric mature B-cell NHL, early referral and supportive care problems in a developing country. Hematology. 2019 Dec; 24(1):79-83 doi: 10.1080/10245332.2018.1510087. Epub 2018 Aug 27.
Guillermo Chantada1 Catherine G. Lam, 2 and Scott C. Howard. Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment British Journal of Haematology, 2019, doi: 10.1111/bjh.15785
N. Otmani, M. Khattab: Oral Burkitt’s lymphoma in children: the Moroccan experience. Int. J. Oral Maxillofac. Surg. 2008; 37: 36–40.
Rivera-Luna, Roberto M.D.; Martinez-Guerra, Guillermo M.D.; Martinez-Avalos, Armando M.D.; Altamirano-Alvarez, Eduardo M.D.; Ayon-Cardenas, Ana M.D.; Cardenas-Cardoz, Rocio M.D.; Borrego-Roman, Rigoberto M.D.; Lanche-Guevara, Teresa M.D.; Lopez-Corella, Eduardo M.D. Treatment of Non-Hodgkin's Lymphoma in Mexican Children: The Effectiveness of Chemotherapy During 13 Malnutrition. [Miscellaneous] American Journal of Pediatric Hematology/Oncology. 9(4):356-366, Winter 1987.
Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45:761-7.